New Era in Melanoma

Mike Hennessy
Published: Wednesday, Sep 27, 2017
Mike Hennessy

OncLive Chairman,

Mike Hennessy
It was just 6 years ago that options for patients with metastatic melanoma began to expand. In 2011, the approval of ipilimumab (Yervoy), the pioneering checkpoint immunotherapy for patients with unresectable or metastatic disease, marked the first milestone. Clinicians treating patients with advanced melanoma now have a toolkit that is stocked with several types of immunotherapies and targeted therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Publication Bottom Border
Border Publication